ライフサイエンスコーパス: cell surface marker

1 major glycoprotein 2 (GP2) as a PP-specific cell surface marker.

2 cells has been difficult without a defining cell surface marker.

3 nto Th17 cells in vitro and in vivo via CD25 cell surface marker.

4 e ISCs from mouse and human tissues based on cell surface markers.

5 ytometry together with various hematopoietic cell surface markers.

6 al nerve, and immunofluorescence staining of cell surface markers.

7 4, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers.

8 her coagulation, inflammatory, or lymphocyte cell surface markers.

9 subpopulation characterized previously using cell surface markers.

10 he result of context-dependent expression of cell surface markers.

11 arly-outgrowth colony-forming unit assay and cell surface markers.

12 ke cysts that selectively incorporate apical cell surface markers.

13 ined challenging due to the lack of specific cell surface markers.

14 eased up-regulation of activation-associated cell surface markers.

15 xpression of both DC and monocyte/macrophage cell surface markers.

16 iling cytokines, intracellular molecules and cell surface markers.

17 an be identified by the presence of specific cell surface markers.

18 oskeleton regulators and the localization of cell surface markers.

19 et been achieved due to the lack of specific cell surface markers.

20 ls that previously identified based on other cell surface markers.

21 y Ab responses due to an absence of specific cell surface markers.

22 using flow cytometry to determine lymphocyte cell surface markers.

23 protein assays for cytokine, chemokine, and cell surface markers.

24 eukemias expressing early B lineage and stem cell surface markers.

25 effect on iDC survival or the expression of cell surface markers.

26 ytokine secretion and expression of specific cell surface markers.

27 essing erythroid, myeloid, lymphoid and stem cell surface markers.

28 cell cycle, and failed to express multiple B-cell surface markers.

29 emokine messenger RNA (mRNA) expression, and cell surface markers.

30 be phenotypically distinguished by very few cell surface markers.

31 pol mRNA, intracellular p24 Gag protein, and cell surface markers.

32 lliliter of blood and the fold expression of cell surface markers.

33 human fetal pancreatic differentiation using cell surface markers.

34 ypically purified from the bone marrow using cell surface markers.

35 re limited by the lack of available specific cell surface markers.

36 ession profiles and identification of unique cell-surface markers.

37 roid progenitor cells that express analogous cell-surface markers.

38 expression of APC (macrophages and dendritic cells) surface markers.

39 unbiased manner a panel of all commonly used cell surface markers (280 genes) from individual cells.

40 ogenase-bright cells expressed CD34 or CD133 cell surface markers (57.0% and 27.1%, respectively), co

41 We show herein that the cell surface marker 6-sulfo LacNAc (slan) can define sla

42 for viral haemagglutinin (HA) expression and cell surface markers 8-16 hours post infection.

43 From the panel of 21 cell surface markers, 9 were overexpressed in fetal prog

44 nfection of DC with live 35000HP caused less cell surface marker activation than infection with heat-

45 also expressed higher levels of more mature cell surface markers, additionally linking inflammasome

46 ses were assessed by measuring expression of cell surface markers (adhesion molecules, fibrinogen-lik

47 Additional cytokines, cell surface markers, adhesion molecules, and accessory

48 ated with respect to endocytosis properties, cell surface markers, allostimulatory activity, and cyto

49 These cell surface markers allowed direct isolation of rare ce

50 Superparamagnetic antibodies specific for cell surface markers allowed imaging of CD4+ T cells, CD

51 the basis of Hoechst exclusion and a single cell-surface marker allows enrichment levels similar to

52 Cell surface marker analysis reveals that PP T cells con

53 ary, we identified GD2 as a new CSC-specific cell surface marker and GD3S as a potential therapeutic

54 These cells continue to express the CD34 cell surface marker and have ongoing telomerase activity

55 thelial cells expressed specific endothelial cell surface markers and also exhibited the capacity for

56 bpopulations of CSCs, characterized by their cell surface markers and colony morphology, which can se

57 to different sub-populations on the basis of cell surface markers and examine their function in an in

58 comprised of distinct subsets with different cell surface markers and functional characteristics and

59 ntional dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse and hu

60 ancer cell line, which we first confirmed by cell surface markers and gene profiling to be highly enr

61 otypes, express telomerase activity, express cell surface markers and genes that characterize human E

62 Peripheral lymphocyte cell surface markers and HLA Ab levels (%PRA and titers)

63 Analysis of cell surface markers and immunoglobulin H gene rearrange

64 MAPK signaling pathways and up-regulation of cell surface markers and intracellular molecules associa

65 re and extent of abnormalities in lymphocyte cell surface markers and NK cell activity in patients wi

66 s include (1) the identification of distinct cell surface markers and other cellular properties in he

67 Changes in cell surface markers and patterns of gene expression are

68 d expression of CD80, CD86, CD40, and MHC-II cell surface markers and production of proinflammatory c

69 this likeness extended into the non-ISCT MSC cell surface markers and trilineage differentiation, whi

70 ubsets based on their expression of specific cell surface markers and used them in our adoptive trans

71 s and healthy control donors share a similar cell-surface marker and gene expression profile.

72 l death (AICD) and expressed a unique set of cell-surface markers and gene profiles.

73 display significantly altered expression of cell-surface markers and produce increased inflammatory

74 ly, neutrophil morphology (nucleus shape and cell-surface markers) and functions (phagocytosis, degra

75 nology for measuring cell entity, evaluating cell surface marker, and peculiarly in the field of stem

76 ion of apoptosis, acquisition of tumorigenic cell surface markers, and epithelial-mesenchymal transit

77 including those encoding effector cytokines, cell surface markers, and key transcription factors.

78 iptional program, expression of B lymphocyte cell surface markers, and reprogramming of cell fate.

79 ptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediate

80 Because many cell surface markers are shared between AML blasts and h

81 wed AME downregulates the expression of such cell surface markers as CD80, CD86, and major histocompa

82 interferon-gamma production, without losing cell surface markers associated with memory.

83 al cells in part by increasing the levels of cell surface markers associated with mesenchymal stem ce

84 We identified cell surface markers associated with repression of p16(I

85 effector T cells, and caused an increase in cell surface markers associated with T(Regs) such as Fox

86 eration of reagents that specifically target cell-surface markers, because transmembrane proteins are

87 in muscle tissue express memory and effector cell surface markers but have sharply attenuated effecto

88 n NMR biosensor that can identify a specific cell surface marker by targeted (129)Xe MRI.

89 Analysis of several cell surface markers by flow cytometry showed that EPC,

90 nel of cytokines, chemokines, receptors, and cell surface markers by RNase protection assays.

91 and FACS analyses demonstrate that specific cell surface markers can be used to discriminate prostat

92 ete subset identified by coexpression of the cell-surface markers CD123 and CCR6.

93 As the cell surface marker CD133 identifies cancer-initiating c

94 The cell surface marker CD133 is frequently used to identify

95 Currently, the cell surface marker CD138 (SDC1) is used for this enrich

96 ive L3 for 48 h showed no alterations in the cell surface markers CD14, CD86, CD83, CD207, E-cadherin

97 imeric monoclonal antibody against the pan B cell surface marker CD20 (rituximab).

98 ammatory T cells into tissues, or target the cell surface marker CD20 (rituximab; Rituxan for hematol

99 data in K562 leukemic cells, we identify the cell surface marker CD24 as co-varying with chromatin ac

100 A new study shows that a cell-surface marker, CD27, identifies the first point of

101 s with great thermogenic potential using the cell surface marker CD29.

102 (MLN), spleen and thymus were labeled for T cell surface markers (CD3, CD4, CD8) and intracellular F

103 The cell surface marker CD34 marks mouse hair follicle bulge

104 including CTNND1 and the early hematopoietic cell surface marker CD34, resulted in reduced leukemic g

105 Using cell surface markers (CD34, CD133, kinase insert domain

106 nterferon-gamma with a unique combination of cell surface markers (CD4(+)CD25(-)CD44(hi)CD62L(lo)) an

107 ed dendritic cells, assessed by increases in cell-surface markers CD40, CD80, CD86, and MHC class I a

108 s of breast cancer stem cells (BCSCs) is the cell surface marker CD44.

109 d stem cell-like characteristics express the cell surface marker CD44.

110 a Matrigel-based differentiation assay, and cell surface markers CD44 and CD24.

111 ese pancreatic cancer stem cells express the cell surface markers CD44, CD24, and epithelial-specific

112 on of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific

113 stage transitions, marked by changes in the cell-surface markers CD44 and ICAM1, and a Nanog-enhance

114 Here, we explored this hypothesis by using 2 cell surface markers, CD44 and CD137, to isolate antitum

115 hat express IL-10, as well as Tr1-associated cell surface markers, CD49b and LAG-3, and transcription

116 Using the natural killer (NK) cell-surface marker CD56 to study NK T cells in peripher

117 )/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26.

118 -surface protein also known as the leukocyte cell-surface marker CD82.

119 n the low nanomolar range, we identified the cell surface marker CD86 as a sensitive surrogate biomar

120 ls based on a variety of phenotypes, such as cell surface markers, cell proliferation and drug respon

121 B in vitro, as measured by the expression of cell surface markers, cellular signaling events, and cyt

122 man MDDCs exposed to galectin-1 up-regulated cell surface markers characteristic of DC maturation (CD

123 ubsets of HPCs examined, including HPCs with cell surface markers consistent with immature hematopoie

124 ssion signatures, morphological changes, and cell surface markers consistent with myeloid maturation.

125 e cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found th

126 within the tumor preferentially express the cell surface markers CTLA-4 and OX40.

127 Given the limited repertoire of cell-surface markers currently available for neural prog

128 oadly characterized by the expression of the cell surface marker CXCR4.

129 etailed study has been hampered by a lack of cell surface markers defining tumor-specific dysfunction

130 Forty cell-surface markers, distinguishing all major leukocyte

131 is approach is that the presence of specific cell surface markers does not directly reflect the trans

132 umor cell (CTC) detection strategies rely on cell surface marker EpCAM and intracellular cytokeratins

133 We demonstrate that by the judicious use of cell surface markers, especially CD11b and CD11c, severa

134 XCL9, CXCL10, CXCL12, CXCL13 and CXCL16) and cell surface marker expression (CD3, CD4 and CXCR3) in p

135 eripheral blood, cutaneous mTregs had unique cell surface marker expression and cytokine production.

136 Although not affecting cell surface marker expression and phagocytotic function

137 ted control iDCs to WT capsule did not alter cell surface marker expression but did elicit IL-8.

138 Cytokine production and cell surface marker expression of murine PP mononuclear

139 normal, displaying no obvious compromise in cell surface marker expression or antibody production ei

140 n in vivo, and except for CD138, plasmablast cell surface marker expression was unaffected.

141 tro proliferation responses, alloreactivity, cell surface marker expression, and antibody production.

142 recipient T cells as assessed by frequency, cell surface marker expression, cytokine production, and

143 T cells showed convergence in the pattern of cell surface marker expression, cytokine profiles, and g

144 n of MEK1/2 did not reduce CT-B induction of cell surface marker expression, it did attenuate CT-B-me

145 nd, when isolated from skeletal muscle using cell surface marker expression, these cells showed compa

146 entiation for at least 25 d, as evidenced by cell surface marker expression.

147 rom the nontumorigenic cancer cells based on cell surface marker expression.

148 ains the decrease in cytokine production and cell surface marker expression.

149 isolation, cells were characterized through cell-surface marker expression and lineage-specific diff

150 and, regardless of methodology for harvest, cell-surface marker expression of CD73, CD90, CD105, and

151 We used cell-surface marker expression to purify from the satell

152 lectively increased polyploidization, mature cell-surface marker expression, and apoptosis of maligna

153 Cell surface markers' expression and chemotaxis were det

154 transmembrane glycoprotein, is an important cell surface marker for both stem cells and cancer stem

155 CCR6 was the best cell surface marker for IL-17A+ cells when compared with

156 Moreover, huEGFRt provides a cell surface marker for in vivo tracking of adoptively t

157 Dual staining for CD68 (a cell surface marker for macrophages) and PCNA was also p

158 xpression of CD83 (previously described as a cell surface marker for mature dendritic cells) on CD4 T

159 We further identified a cell surface marker for prospective isolation of iNCs, w

160 MUC16 is a well-validated cell surface marker for serous adenocarcinomas of the ov

161 matic stem cells, and it is widely used as a cell surface marker for the isolation and characterizati

162 Our identification of new cell surface markers for enriching mammosphere-initiatin

163 Existing cell surface markers for GSC are developed from embryoni

164 Our analysis identified 24 new/potential cell surface markers for murine fetal hepatic stem cells

165 ss I molecules offers unique cancer-specific cell surface markers for the identification and targetin

166 ceptor (MC1R), which has been evaluated as a cell-surface marker for melanoma.

167 timulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer.

168 In this study, we attempted to identify cell-surface markers for leukemia-initiating cells in FA

169 Cell-surface markers for prospective isolation of stem c

170 of commercial antibodies, we have identified cell-surface markers for the separation of pancreatic ce

171 cently, a simple phenotype for HSCs based on cell surface markers from the signaling lymphocyte activ

172 ood, we acquired an immunological profile of cell-surface markers from healthy control and untreated

173 ssessment, nitro-blue tetrazolium reduction, cell-surface markers, genome-wide patterns of gene expre

174 h all the hallmarks of stem cells, including cell surface markers, global gene expression profiles, a

175 ent, both targeting the erythrocyte-specific cell surface marker glycophorin A.

176 However, lack of known unique mesangial cell surface markers has hampered this process.

177 allowing detection of increasing numbers of cell surface markers, has challenged the traditional tec

178 ietic, neural, and skeletal muscle, and stem cell surface markers have been characterized.

179 rious combinations of antibodies directed to cell surface markers have been used to isolate human and

180 Several cell-surface markers have been reported to identify cand

181 the basis of the differential expression of cell-surface markers, here we identify a mesenchymal str

182 ific membrane antigen (PSMA), a prototypical cell surface marker highly overexpressed in prostate can

183 utrophils, fibroblasts, and lymphocytes; and cell surface markers, ie, F4/80, CD11b, CD11c, and Ly-6C

184 ify and purify anergic T cells by a distinct cell surface marker in an autoimmune disease and paves t

185 he up-regulation of macrophage/hematopoietic cell surface markers in a large proportion of NIH 3T3 ce

186 Novel cell surface markers in adult progenitor cells included

187 e due to the impaired expression of relevant cell surface markers in Eklf(-/-) erythroid cells.

188 o studied expression of the identified novel cell surface markers in fetal rat liver progenitor cells

189 S), we examined mRNA expression of dendritic cell surface markers in individual sporadic ALS (sALS),

190 In this work, we studied progenitor/oval cell surface markers in the liver of rats subjected to 2

191 Persistence of respective cell surface markers in vitro is confirmed both by flow

192 responses, alloreactivity, and expression of cell surface markers in vitro.

193 selection using an optimized combination of cell surface markers including CD30.

194 n be separated into two populations based on cell surface markers including CD34.

195 ells that exhibit differential expression of cell surface markers, including CD105 (or endoglin), Thy

196 ethod was reported, using the SLAM family of cell-surface markers, including CD150 (SlamF1), to offer

197 Although exhibiting cell surface markers indicative of activation, the IL-10

198 roteins and were monitored for expression of cell surface markers indicative of maturation.

199 The transcriptional profile identified 2 cell-surface markers, ITGA6 and NGFR, which can be used

200 n inflammatory cell numbers and cytokine and cell-surface marker levels on monocytes and macrophages.

201 gland stem cells (MaSCs) using combinatorial cell surface markers (Lin(-)CD24(+)CD29(h)CD49f(h)) has

202 lation based on the expression profiles of 2 cell-surface markers LNGFR (CD271) and THY-1 (CD90).

203 re the identification of TIM3 as an AML stem cell surface marker more highly expressed on multiple sp

204 PSMA is a unique cell surface marker, negatively regulated by androgen an

205 We have isolated rare cells bearing the NK cell surface marker NK1.1, as well as the dendritic cell

206 rapidly upregulate the expression of the NK cell-surface marker NK1.1 in response to MSU crystals bu

207 ty in vitro but lacked expression of myeloid cell surface markers normally seen with MLL-CBP.

208 e attenuates acute loss of the developing OL cell surface marker O1 and the mature OL marker MBP (mye

209 ir expression of CD4, CD8, naive, and memory cell-surface markers, occupy distinct homeostatic compar

210 CD44 is commonly used as a cell surface marker of cancer stem-like cells in epithel

211 xpression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.

212 e DLL1(+) cluster, revealed it to be a novel cell surface marker of human epidermal stem cells.

213 11 receptor alpha subunit (IL-11Ralpha) as a cell surface marker of tumor progression that correlates

214 Doubly deficient T cells displayed cell surface markers of activation yet were significantl

215 ukocytes (VLC), due to sharing functions and cell surface markers of both dendritic cells and endothe

216 protein resulted in increased expression of cell surface markers of DC maturation and an increase in

217 that a group of immature myeloid cells with cell surface markers of Gr-1(+) CD11b(+) are highly enri

218 ion, cytokine production, proliferation, and cell surface markers of immune cells between GA-treated

219 ry CD8 T cells from naive old mice expressed cell surface markers of memory in addition to receptors

220 MSCs) were established and characterized for cell surface markers of mesenchymal stem cell origin in

221 also known as CD143), a recently identified cell-surface marker of adult human hematopoietic stem ce

222 CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells

223 associated with GVHD leads to expression of cell surface markers on both effector and regulatory T c

224 The expression of lymphoid cell surface markers on PBMC and splenocytes of mice hom

225 S, and microglial activation was assessed by cell surface marker or phospho-MAPK immunofluorescence.

226 eomic or flow cytometric characterization of cell surface markers or adoptive transfer.

227 ls (CSCs) can be identified by expression of cell surface markers or enzymatic activity, but these me

228 intercellular adhesion, without knowledge of cell-surface markers or intracellular proteins.

229 Flow cytometry utilizing the cell surface markers p75 and HNK-1 was used to isolate l

230 haracteristics such as cell cycle status and cell surface marker phenotype, they respond to different

231 These results demonstrate that CD96 is a cell surface marker present on many AML-LSC and may serv

232 ese results demonstrate that IL-3Ralpha is a cell-surface marker present on FA-AML leukemia-initiatin

233 vity was confirmed by examining cytokine and cell surface marker production in bone-marrow-derived de

234 n cytokine-supplemented medium changed their cell surface marker profile and gene expression pattern

235 sms are cells characterized by a CD44+/CD24- cell surface marker profile.

236 over 24 h, as indicated by up-regulation of cell surface marker proteins CD40, CD80, and CD86.

237 OV-1 antigen, a6 integrin, and connexin 43), cell surface markers recently identified by us (CD44, CD

238 in rat tissue, they distinctively express a cell surface marker recognized by the SE-1 antibody.

239 cycle, lowered levels of macrophage-specific cell surface markers, resistance to Legionella pneumophi

240 ation; SP) in conjunction with canonical HSC cell-surface markers (Sca-1, c-Kit, and lineage markers)

241 When combined with high-throughput cell surface marker screening, this approach facilitates

242 This study identifies FolR1 as a new cell surface marker selectively expressed in mesDA proge

243 T1/ST2 is a stable cell surface marker selectively expressed on type 2 T he

244 The antennal lobe neuropil expressed the cell surface marker semaphorin 1a.

245 Analysis of cell surface markers showed an age-dependent increase in

246 These MDSCs express a cell surface marker signature (CD11b(+) Gr-1(+) Ly6C(+))

247 n is reliant on the presence of well-defined cell surface markers specific for diverse progenitor pop

248 We identified novel cell surface markers specific for hepatic progenitor/ova

249 cells as demonstrated by expression of stem cell surface markers such as aldehyde dehydrogenase 1, s

250 m is complicated by the shared expression of cell surface markers such as CD11c.

251 ) are commonly purified by the expression of cell surface markers such as CD34.

252 Identification of cell surface markers sufficient to purify Treg cells exp

253 ed by a remarkable up-regulation of specific cell surface markers, suggesting that LPS stimulation le

254 n of MSC with both endothelial and pericytic cell surface markers suppresses the homing of cancer cel

255 olobus purpureas agglutinin (TPA) as a novel cell surface marker that allows for such delineation.

256 These data suggest that AA4.1 is a cell surface marker that can identify the earliest lymph

257 CD20 is a B cell surface marker that is expressed in various stages

258 We identified 33 transcripts encoding cell surface markers that are differentially expressed b

259 e and chemokine responses, and expression of cell surface markers that are related to T cell activati

260 Cluster designation (CD) antigens are cell surface markers that can be used to identify consti

261 nitive endoderm with the goal of identifying cell surface markers that can be used to track the devel

262 t LSC, one potential strategy is to identify cell surface markers that can distinguish LSC from norma

263 We sought to delineate cell surface markers that could distinguish NK cells tha

264 acteristics, as well as the precise panel of cell surface markers that uniquely define this newly des

265 ha,and IL-2, and up-regulation of numerous T cell surface markers that would promote T-T Ag presentat

266 These results reveal a cell-surface marker that delineates functional activity

267 , zymosan, heat-killed or live bacteria, and cell-surface markers that coexpress with FR were identif

268 We identify cell-surface markers that delineate a series of stress e

269 ptor type I and II (CD121a/CD121b) as unique cell-surface markers that distinguish activated Tregs fr

270 lls have been hampered by a lack of suitable cell-surface markers that specifically enable their puri

271 cell subsets that display either CD4 or CD8 cell surface markers, the leukemic cell is exclusively o

272 ltiple defects in the expression of effector cell surface markers, the synthesis of cytokines, and in

273 Upon recognizing the targeted cell-surface marker, the APH enters the host cell via en

274 e cell lines were negative for hematopoietic cell surface markers, they gave rise to hematopoietic co

275 D(2) receptor, CRTH2, the best selective Th2-cell surface marker to date.

276 op an assay based on loss of expression of a cell surface marker to monitor epigenetic instability at

277 ins on fibroblast cells, which are potential cell surface markers to differentiate endothelial and fi

278 tential in part independent of commonly used cell surface markers to discriminate effector and memory

279 We have used specific cell surface markers to examine the association of NG2 c

280 nhanced green fluorescent protein (eGFP) and cell surface markers to FACS-isolate DeltaSox2-eGFP(+) G

281 is due, in part, to the difficulty of using cell surface markers to identify CD4(+)CD25(+) T reg cel

282 we combine H2B-GFP-based pulse-chasing with cell-surface markers to distinguish quiescent from proli

283 ave used flow cytometry and a defined set of cell-surface markers to identify and subsequently isolat

284 ly carried out by quantification of multiple cell surface markers, transcription factors and cytokine

285 eries of heterogeneous subpopulations in its cell surface markers, tumorigenicity, invasion and metas

286 The cells lacked expression of cell surface markers typically expressed by germinal cen

287 ver based on the expression of CD4 and other cell surface markers uniquely expressed by pDCs.

288 Sca-1 is a cell surface marker used to identify hematopoietic stem

289 They discovered a panel of cell surface markers useful for isolating living hair fo

290 The specificity of progenitor/oval cell surface markers was confirmed by ISH and double IF

291 Additional cell surface markers were also used to quantify differen

292 he differential expression patterns of these cell surface markers were dependent on Ly49H recognition

293 Cell surface markers were screened for their ability to

294 Antibodies against the following cell surface markers were used: CD45 (leukocytes), CD3 (

295 cently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90%

296 Cs and a germline seminoma that share a CD38 cell-surface marker, which collectively defines likely p

297 CX3CR1, a cell surface marker whose expression is associated with

298 lyzed for the expression of CD105 and CD166, cell surface markers whose coexpression defines mesenchy

299 Initially, we determined that the 3 cell surface markers widely used to identify naive T cel

300 r-, costimulation-, or activation-associated cell surface markers yet were associated with lower Ly6C